S1PR2 and breast cancer: In breast cancer cell lines, however, the use of tamoxifen and medroxyprogesterone result in the downregulation of S1PR3 and stimulation of S1PR2 with activation of autophagy of the breast cancer cells towards death, again demonstrating the detrimental role of S1P pathway activation in cancer [30].